Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bolt Projects Holdings, Inc.BSLK · Entity 65458 | Director | November 25, 2024 | November 27, 2024 |
| LISATA THERAPEUTICS, INC.LSTA · Entity 7814 | Director | January 09, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bolt Projects Holdings, Inc.
Report date November 25, 2024 · Filed November 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 72,500 |
Ending reported balance
After 2024-11-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-11-25 · Grant · Acquired 22,500 · Balance 57,500 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer's common stock. F2: Represents an award of RSUs, which vests in three equal annual installments commencing on August 13, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Row 2 · 2024-11-25 · Grant · Acquired 15,000 · Balance 72,500 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer's common stock. F3: Represents an award of RSUs, which vests in full on the earlier to occur of (i) August 13, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders following the grant date, subject to the Reporting Person's continued service on the Board through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer's common stock.
F2: Represents an award of RSUs, which vests in three equal annual installments commencing on August 13, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
F3: Represents an award of RSUs, which vests in full on the earlier to occur of (i) August 13, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders following the grant date, subject to the Reporting Person's continued service on the Board through the applicable vesting date.
LISATA THERAPEUTICS, INC.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 95,815 |
Reported balance
After 2026-01-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 30,456 · Balance 95,815 F1: Represents 30,456 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2027. F2: Includes 30,456 unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 30,456 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2027.
F2: Includes 30,456 unvested restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CAMBREX CORP
Report date December 04, 2019 · Filed December 05, 2019
Section 16 reporting ended · disclosed 2019-12-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-12-04 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2019-12-04 · Exercise / conversion · Acquired 50,000 · Balance 163,706 Row 2 · 2019-12-04 · Exercise / conversion · Acquired 50,000 · Balance 213,706 Row 3 · 2019-12-04 · Exercise / conversion · Acquired 38,000 · Balance 251,706 Row 4 · 2019-12-04 · Exercise / conversion · Acquired 30,000 · Balance 281,706 Row 5 · 2019-12-04 · Grant · Acquired 65,500 · Balance 347,206 F1: Each Company restricted stock unit subject to performance-vesting conditions (each, a "Company PSU") that was outstanding immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00, multiplied by the total number of shares of Company Common Stock subject to such Company PSU, with any performance-based vesting conditions deemed achieved at the greater of (x) target levels of performance and (y) actual levels of performance, without pro-ration. Row 6 · 2019-12-04 · Sale · Disposed 347,206 · Balance 0 F2: Disposed of for $60.00 per share pursuant to the terms of that certain Agreement and Plan of Merger dated as of August 7, 2019, by and among Catalog Intermediate Inc. ("Parent"), Catalog Merger Sub ("Merger Sub"), each entities controlled by investment funds advised by Permira Advisors LLC, and the Company (the "Merger Agreement"). All terms capitalized but not defined shall have the respective meanings given to them in the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.36 | Direct | 0 |
Reported balance
After 2019-12-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-12-04 · Exercise / conversion · Acquired 50,000 · Balance 0 F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.65 | Direct | 0 |
Reported balance
After 2019-12-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-12-04 · Exercise / conversion · Acquired 50,000 · Balance 0 F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.64 | Direct | 0 |
Reported balance
After 2019-12-04 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-12-04 · Exercise / conversion · Acquired 38,000 · Balance 0 F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.61 | Direct | 0 |
Reported balance
After 2019-12-04 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-12-04 · Exercise / conversion · Acquired 30,000 · Balance 0 F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Company restricted stock unit subject to performance-vesting conditions (each, a "Company PSU") that was outstanding immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00, multiplied by the total number of shares of Company Common Stock subject to such Company PSU, with any performance-based vesting conditions deemed achieved at the greater of (x) target levels of performance and (y) actual levels of performance, without pro-ration.
F2: Disposed of for $60.00 per share pursuant to the terms of that certain Agreement and Plan of Merger dated as of August 7, 2019, by and among Catalog Intermediate Inc. ("Parent"), Catalog Merger Sub ("Merger Sub"), each entities controlled by investment funds advised by Permira Advisors LLC, and the Company (the "Merger Agreement"). All terms capitalized but not defined shall have the respective meanings given to them in the Merger Agreement.
F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2018 Filed Jun 12, 2018 21:13 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 55,000 | $12.46 | $685,300.00 |
DisclosureSEC source: 0001209191-18-037357 · doc4.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| May 07, 2018 Filed Aug 7, 2018 17:56 UTC | CAMBREX CORP CBM · Entity 153359 | GrantCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-045748 · doc4.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,328 F1 · shares: Pursuant to settlement of a performance share award. Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 21:05 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantRestricted Stock Units · Derivative | 8,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-001699 · tv483050_4.xml · derivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,747 Underlying: Common Stock · 8,747 shares Expires 2028-01-08 F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on the date that is one year from the date of grant. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 17:02 UTC | CAMBREX CORP CBM · Entity 153359 | GrantStock Option (right to buy) · Derivative | 38,000 | $0.00 Strike: $45.64 | $0.00 |
DisclosureSEC source: 0001437749-17-018047 · rdgdoc.xml · derivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2024-10-30 F1 · derivative.exercise_date: The option representing a right to purchase a total of 38,000 shares becomes exercisable in four equal installments beginning October 30, 2018, which is the first anniversary of the date on which the option was granted. Read SEC document |
| October 02, 2017 Filed Oct 3, 2017 17:10 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $5.72 | $0.00 |
DisclosureSEC source: 0001437749-17-016710 · rdgdoc.xml · derivative · entry 3 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2018-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option representing a right to purchase 100,000 shares became exercisable in four equal installments beginning October 18, 2012, which was the first anniversary of the date on which the option was granted. Read SEC document |
| October 02, 2017 Filed Oct 3, 2017 17:10 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 4,000 | $54.96 | $219,830.40 |
DisclosureSEC source: 0001437749-17-016710 · rdgdoc.xml · nonDerivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,328 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.70 to $55.25 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4. Read SEC document |
| October 02, 2017 Filed Oct 3, 2017 17:10 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 4,000 | $5.72 | $22,880.00 |
DisclosureSEC source: 0001437749-17-016710 · rdgdoc.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 16:05 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $5.72 | $0.00 |
DisclosureSEC source: 0001437749-17-015570 · rdgdoc.xml · derivative · entry 4 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 12,000 shares Expires 2018-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option representing a right to purchase 100,000 shares became exercisable in four equal installments beginning October 18, 2012, which was the first anniversary of the date on which the option was granted. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 16:05 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 1,298 | $52.08 | $67,600.10 |
DisclosureSEC source: 0001437749-17-015570 · rdgdoc.xml · nonDerivative · entry 3 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,328 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.2500 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 16:05 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 10,702 | $51.47 | $550,786.99 |
DisclosureSEC source: 0001437749-17-015570 · rdgdoc.xml · nonDerivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,626 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.95 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 16:05 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 12,000 | $5.72 | $68,640.00 |
DisclosureSEC source: 0001437749-17-015570 · rdgdoc.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 16:01 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $5.72 | $0.00 |
DisclosureSEC source: 0001437749-17-013575 · rdgdoc.xml · derivative · entry 4 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 12,000 shares Expires 2018-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option representing a right to purchase 100,000 shares became exercisable in four equal installments beginning October 18, 2012, which was the first anniversary of the date on which the option was granted Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 16:01 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 6,439 | $61.65 | $396,964.35 |
DisclosureSEC source: 0001437749-17-013575 · rdgdoc.xml · nonDerivative · entry 3 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,328 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.55 to $62.05 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4 Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 16:01 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 5,561 | $61.09 | $339,705.36 |
DisclosureSEC source: 0001437749-17-013575 · rdgdoc.xml · nonDerivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,767 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.55 to $61.5250 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4 Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 16:01 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 12,000 | $5.72 | $68,640.00 |
DisclosureSEC source: 0001437749-17-013575 · rdgdoc.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 16:05 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option ( right to buy) · Derivative | 12,000 | $0.00 Strike: $5.72 | $0.00 |
DisclosureSEC source: 0001437749-17-012228 · rdgdoc.xml · derivative · entry 3 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 12,000 shares Expires 2018-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option representing a right to purchase 100,000 shares became exercisable in four equal installments beginning October 18, 2012 which was the first anniversary of the date on which the option was granted Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 16:05 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 12,000 | $59.66 | $715,906.80 |
DisclosureSEC source: 0001437749-17-012228 · rdgdoc.xml · nonDerivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,328 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.45 to $60.00 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4 Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 16:05 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 12,000 | $5.72 | $68,640.00 |
DisclosureSEC source: 0001437749-17-012228 · rdgdoc.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 16:05 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $5.72 | $0.00 |
DisclosureSEC source: 0001437749-17-010536 · rdgdoc.xml · derivative · entry 4 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 12,000 shares Expires 2018-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option representing a right to purchase 100,000 shares became exercisable in four equal installments beginning October 18, 2012 which was the first anniversary of the date on which the option was granted Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 16:05 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 6,200 | $54.65 | $338,824.42 |
DisclosureSEC source: 0001437749-17-010536 · rdgdoc.xml · nonDerivative · entry 3 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,328 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.125 to $55.10 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4 Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 16:05 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 5,800 | $53.69 | $311,406.06 |
DisclosureSEC source: 0001437749-17-010536 · rdgdoc.xml · nonDerivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,528 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.325 to $54.10 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4 Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 16:05 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 12,000 | $5.72 | $68,640.00 |
DisclosureSEC source: 0001437749-17-010536 · rdgdoc.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 Read SEC document |
| May 16, 2017 Filed May 18, 2017 21:00 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 2,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-028453 · v467408_4.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,065 F1 · shares: Represents an award of 2,565 Restricted Stock Units granted under the Issuer's 2015 Equity Compensation Plan that will vest on May 16, 2018. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. F2 · balance_after: Includes 750 shares of unvested restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on June 22, 2017, 1,650 shares of unvested restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on January 9, 2018, 2,565 shares of unvested Restricted Stock Units granted under the Issuer's 2015 Equity Compensation Plan that will vest on May 16, 2018 and 312 shares of unvested restricted stock granted under the Issuer's 2009 Equity Compensation Plan that will vest quarterly through June 2, 2018. Read SEC document |
| May 01, 2017 Filed May 2, 2017 16:16 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $5.72 | $0.00 |
DisclosureSEC source: 0001437749-17-007743 · rdgdoc.xml · derivative · entry 5 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 12,000 shares Expires 2018-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option representing a right to purchase 100,000 shares became exercisable in four equal installments beginning October 18, 2012 which was the first anniversary of the date on which the option was granted Read SEC document |
| May 01, 2017 Filed May 2, 2017 16:16 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 300 | $59.72 | $17,915.01 |
DisclosureSEC source: 0001437749-17-007743 · rdgdoc.xml · nonDerivative · entry 4 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,328 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.60 to $59.85 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 4 to this Form 4 Read SEC document |
| May 01, 2017 Filed May 2, 2017 16:16 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 1,000 | $58.86 | $58,857.50 |
DisclosureSEC source: 0001437749-17-007743 · rdgdoc.xml · nonDerivative · entry 3 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,628 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.55 to $59.40 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4 Read SEC document |
| May 01, 2017 Filed May 2, 2017 16:16 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 10,700 | $58.09 | $621,572.63 |
DisclosureSEC source: 0001437749-17-007743 · rdgdoc.xml · nonDerivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,628 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.55 to $58.45 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4 Read SEC document |
| May 01, 2017 Filed May 2, 2017 16:16 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 12,000 | $5.72 | $68,640.00 |
DisclosureSEC source: 0001437749-17-007743 · rdgdoc.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 Read SEC document |
| April 03, 2017 Filed Apr 3, 2017 17:33 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $5.72 | $0.00 |
DisclosureSEC source: 0001437749-17-005931 · rdgdoc.xml · derivative · entry 3 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 12,000 shares Expires 2018-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option representing a right to purchase 100,000 shares became exercisable in four equal installments beginning October 18, 2012 which was the first anniversary of the date on which the option was granted Read SEC document |
| April 03, 2017 Filed Apr 3, 2017 17:33 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 12,000 | $54.58 | $654,960.00 |
DisclosureSEC source: 0001437749-17-005931 · rdgdoc.xml · nonDerivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,328 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.2250 to $55.20 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4 Read SEC document |
| April 03, 2017 Filed Apr 3, 2017 17:33 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 12,000 | $5.72 | $68,640.00 |
DisclosureSEC source: 0001437749-17-005931 · rdgdoc.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 16:26 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $5.72 | $0.00 |
DisclosureSEC source: 0001437749-17-003673 · rdgdoc.xml · derivative · entry 3 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,000 Underlying: Common Stock · 12,000 shares Expires 2018-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option representing a right to purchase 100,000 shares became exercisable in four equal installments beginning October 18, 2012 which was the first anniversary of the date on which the option was granted Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 16:26 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 12,000 | $56.70 | $680,444.40 |
DisclosureSEC source: 0001437749-17-003673 · rdgdoc.xml · nonDerivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,328 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.35 to $57.10 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4 Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 16:26 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 12,000 | $5.72 | $68,640.00 |
DisclosureSEC source: 0001437749-17-003673 · rdgdoc.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 17:00 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 4,326 | $53.10 | $229,710.60 |
DisclosureSEC source: 0001437749-17-002784 · rdgdoc.xml · nonDerivative · entry 4 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,328 Read SEC document |
| February 13, 2017 Filed Feb 14, 2017 17:33 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $5.72 | $0.00 |
DisclosureSEC source: 0001437749-17-002462 · rdgdoc.xml · derivative · entry 6 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,000 Underlying: Common Stock · 12,000 shares Expires 2018-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option representing a right to purchase 100,000 shares became exercisable in four equal installments beginning October 18, 2012, which was the first anniversary of the date on which the option was granted Read SEC document |
| February 13, 2017 Filed Feb 14, 2017 17:33 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 100 | $52.75 | $5,275.00 |
DisclosureSEC source: 0001437749-17-002462 · rdgdoc.xml · nonDerivative · entry 5 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,150 F5 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 Read SEC document |
| February 13, 2017 Filed Feb 14, 2017 17:33 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 11,900 | $52.09 | $619,859.10 |
DisclosureSEC source: 0001437749-17-002462 · rdgdoc.xml · nonDerivative · entry 4 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,250 F5 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.73 to $52.70 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4 Read SEC document |
| February 13, 2017 Filed Feb 14, 2017 17:33 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 12,000 | $5.72 | $68,640.00 |
DisclosureSEC source: 0001437749-17-002462 · rdgdoc.xml · nonDerivative · entry 3 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 17:33 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 1,912 | $53.36 | $102,014.76 |
DisclosureSEC source: 0001437749-17-002462 · rdgdoc.xml · nonDerivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,150 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.35 to $53.40 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4 Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 17:33 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 49,266 | $52.62 | $2,592,573.98 |
DisclosureSEC source: 0001437749-17-002462 · rdgdoc.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,062 F1 · shares: Broker-assisted sale of which 38,936 shares sold were to cover the payment of withholding tax liability arising from the settlement of a performance share award granted on February 7, 2017 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.25 to $53.20 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4 Read SEC document |
| February 09, 2017 Filed Feb 17, 2017 17:00 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommonStock | 2,191 | $52.30 | $114,589.30 |
DisclosureSEC source: 0001437749-17-002784 · rdgdoc.xml · nonDerivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,050 Read SEC document |
| February 09, 2017 Filed Feb 17, 2017 17:00 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 12,909 | $52.25 | $674,495.25 |
DisclosureSEC source: 0001437749-17-002784 · rdgdoc.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,241 Read SEC document |
| February 07, 2017 Filed Feb 8, 2017 16:49 UTC | CAMBREX CORP CBM · Entity 153359 | GrantCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-001932 · rdgdoc.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,328 F1 · shares: Pursuant to settlement of a performance share award Read SEC document |
| January 09, 2017 Filed Jan 31, 2017 23:50 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantOptions to Purchase Common Stock · Derivative | 2,750 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001144204-17-005182 · v458000_4.xml · derivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Underlying: Common Stock · 2,750 shares Expires 2027-01-09 Read SEC document |
| January 09, 2017 Filed Jan 31, 2017 23:50 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-005182 · v458000_4.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 F1 · shares: Represents 1,650 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on January 9, 2018. F2 · balance_after: Includes 2,775 shares of unvested restricted stock granted under the Issuer's compensation plans. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 21:22 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 50,000 | $50.87 | $2,543,500.00 |
DisclosureSEC source: 0001437749-16-042121 · rdgdoc.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,328 F1 · price: The price reported in column 4 in Table 1 is a weighted average price. These shares were sold in multiple transactions ranging from $50.75 to $51.25 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in the footnote (1) to this Form 4. Read SEC document |
| October 26, 2016 Filed Oct 28, 2016 16:07 UTC | CAMBREX CORP CBM · Entity 153359 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $40.65 | $0.00 |
DisclosureSEC source: 0000820081-16-000061 · edgar.xml · derivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2023-10-26 F1 · derivative.exercise_date: The option, representing a right to purchase a total of 50,000 shares, becomes exercisable in four equal installments beginning on October 26, 2017, which is the first anniversary of the date on which the option was granted Read SEC document |
| February 15, 2015 Filed Feb 17, 2017 17:00 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 4,396 | $52.75 | $231,889.00 |
DisclosureSEC source: 0001437749-17-002784 · rdgdoc.xml · nonDerivative · entry 3 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,654 Read SEC document |
| February 07, 2007 Filed Feb 8, 2017 16:49 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 5,000 | $55.00 | $275,000.00 |
DisclosureSEC source: 0001437749-17-001932 · rdgdoc.xml · nonDerivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,328 F2 · shares: Broker-assisted sale of which all shares sold were to cover a portion of the payment of withholding tax liability arising from the settlement of performance share award Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.